The major advantages of monolithic phases are their ability to withstand high mobile phase flow rates and the rapid separations at low back pressure that can be achieved with their use.
A reader recently asked:
What are the advantages of monolithic stationary phases for liquid chromatography?
The major advantages of monolithic phases are their ability to withstand high mobile phase flow rates and the rapid separations at low back pressure that can be achieved with their use. Commercially available monolithic stationary phases have been created from materials such as polymethacrylate and polystyrene copolymers, bonded silica, functionalized cellulose, and polyacrylamide-based copolymers.
Modes of separation include ion-exchange, hydrophilic interaction, reversed- and normal-phase, and affinity chromatography. More information about monolithic phases can be found in an article by Frantisek Svec of the University of California, Berkeley, at the following link: http://www.lcgcmag.com/lcgc/article/articleDetail.jsp?id=158783.
Questions?LCGC technical editor Steve Brown will answer your technical questions. Each month, one question will be selected to appear in this space, so we welcome your submissions. Please send all questions to the attention of "Ask the Editor" at lcgcedit@lcgcmag.com. We look forward to hearing from you.
RAFA 2024 Highlights: Contemporary Food Contamination Analysis Using Chromatography
November 18th 2024A series of lectures focusing on emerging analytical techniques used to analyse food contamination took place on Wednesday 6 November 2024 at RAFA 2024 in Prague, Czech Republic. The session included new approaches for analysing per- and polyfluoroalkyl substances (PFAS), polychlorinated alkanes (PCAS), Mineral Oil Hydrocarbons (MOH), and short- and medium-chain chlorinated paraffins (SCCPs and MCCPs).
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.